vs
Side-by-side financial comparison of Cronos Group Inc. (CRON) and Mind Medicine (MindMed) Inc. (DFTX). Click either name above to swap in a different company.
Cronos Group Inc. is the larger business by last-quarter revenue ($44.5M vs $906.0K, roughly 49.2× Mind Medicine (MindMed) Inc.). Cronos Group Inc. runs the higher net margin — -4.1% vs -2634.0%, a 2629.9% gap on every dollar of revenue. On growth, Cronos Group Inc. posted the faster year-over-year revenue change (47.0% vs -16.1%).
Cronos Group Inc. is a global cannabinoid firm specializing in cultivation, processing, and distribution of cannabis-derived products including wellness supplements, consumer goods, and medical cannabis. It serves North America, Europe, and Asia Pacific, catering to regulated recreational and medical consumer segments with quality-controlled offerings.
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
CRON vs DFTX — Head-to-Head
Income Statement — Q4 2025 vs Q4 2023
| Metric | | |
|---|---|---|
| Revenue | $44.5M | $906.0K |
| Net Profit | $-1.8M | $-23.9M |
| Gross Margin | 36.4% | — |
| Operating Margin | -16.8% | -2450.8% |
| Net Margin | -4.1% | -2634.0% |
| Revenue YoY | 47.0% | -16.1% |
| Net Profit YoY | -104.2% | -386.7% |
| EPS (diluted) | $-0.01 | $-0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.5M | — | ||
| Q3 25 | $36.3M | — | ||
| Q2 25 | $33.5M | — | ||
| Q1 25 | $32.3M | — | ||
| Q4 24 | $30.3M | — | ||
| Q3 24 | $34.3M | — | ||
| Q2 24 | $27.8M | — | ||
| Q1 24 | $25.3M | — |
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $26.0M | — | ||
| Q2 25 | $-39.7M | — | ||
| Q1 25 | $6.1M | — | ||
| Q4 24 | $43.7M | — | ||
| Q3 24 | $8.3M | — | ||
| Q2 24 | $-8.8M | — | ||
| Q1 24 | $-2.2M | — |
| Q4 25 | 36.4% | — | ||
| Q3 25 | 50.4% | — | ||
| Q2 25 | 43.4% | — | ||
| Q1 25 | 42.6% | — | ||
| Q4 24 | 35.7% | — | ||
| Q3 24 | 10.5% | — | ||
| Q2 24 | 22.7% | — | ||
| Q1 24 | 17.7% | — |
| Q4 25 | -16.8% | — | ||
| Q3 25 | -1.4% | — | ||
| Q2 25 | -15.9% | — | ||
| Q1 25 | -12.6% | — | ||
| Q4 24 | -37.5% | — | ||
| Q3 24 | -98.2% | — | ||
| Q2 24 | -56.1% | — | ||
| Q1 24 | -63.1% | — |
| Q4 25 | -4.1% | — | ||
| Q3 25 | 71.4% | — | ||
| Q2 25 | -118.7% | — | ||
| Q1 25 | 19.0% | — | ||
| Q4 24 | 144.3% | — | ||
| Q3 24 | 24.4% | — | ||
| Q2 24 | -31.5% | — | ||
| Q1 24 | -8.9% | — |
| Q4 25 | $-0.01 | — | ||
| Q3 25 | $0.07 | — | ||
| Q2 25 | $-0.10 | — | ||
| Q1 25 | $0.02 | — | ||
| Q4 24 | $0.12 | — | ||
| Q3 24 | $0.02 | — | ||
| Q2 24 | $-0.02 | — | ||
| Q1 24 | $-0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $831.8M | $99.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $78.1M |
| Total Assets | $1.2B | $124.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $831.8M | — | ||
| Q3 25 | $824.2M | — | ||
| Q2 25 | $834.4M | — | ||
| Q1 25 | $837.8M | — | ||
| Q4 24 | $858.8M | — | ||
| Q3 24 | $862.0M | — | ||
| Q2 24 | $848.2M | — | ||
| Q1 24 | $855.1M | — |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.8M | $-20.6M |
| Free Cash FlowOCF − Capex | $9.7M | — |
| FCF MarginFCF / Revenue | 21.8% | — |
| Capex IntensityCapex / Revenue | 4.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $149.0K | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.8M | — | ||
| Q3 25 | $13.3M | — | ||
| Q2 25 | $2.8M | — | ||
| Q1 25 | $-2.1M | — | ||
| Q4 24 | $7.7M | — | ||
| Q3 24 | $11.6M | — | ||
| Q2 24 | $1.7M | — | ||
| Q1 24 | $-2.2M | — |
| Q4 25 | $9.7M | — | ||
| Q3 25 | $8.8M | — | ||
| Q2 25 | $-1.0M | — | ||
| Q1 25 | $-17.4M | — | ||
| Q4 24 | $4.2M | — | ||
| Q3 24 | $5.2M | — | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | $-3.9M | — |
| Q4 25 | 21.8% | — | ||
| Q3 25 | 24.3% | — | ||
| Q2 25 | -3.0% | — | ||
| Q1 25 | -53.8% | — | ||
| Q4 24 | 13.8% | — | ||
| Q3 24 | 15.1% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | -15.5% | — |
| Q4 25 | 4.8% | — | ||
| Q3 25 | 12.3% | — | ||
| Q2 25 | 11.5% | — | ||
| Q1 25 | 47.3% | — | ||
| Q4 24 | 11.7% | — | ||
| Q3 24 | 18.7% | — | ||
| Q2 24 | 2.6% | — | ||
| Q1 24 | 6.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.34× | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | 1.39× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRON
| Cannabis Flower | $33.7M | 76% |
| Cannabis Extracts | $10.8M | 24% |
DFTX
Segment breakdown not available.
